title: Inhibition of IL-1beta improves fatigue in type 2 diabetes.
authors.forename: Claudia
authors.initials: C
authors.lastname: Cavelti-Weder
authors.forename: Romana
authors.initials: R
authors.lastname: Furrer
authors.forename: Cornelia
authors.initials: C
authors.lastname: Keller
authors.forename: Andrea
authors.initials: A
authors.lastname: Babians-Brunner
authors.forename: Alan M
authors.initials: AM
authors.lastname: Solinger
authors.forename: H
authors.initials: H
authors.lastname: Gast
authors.forename: A
authors.initials: A
authors.lastname: Fontana
authors.forename: Marc Y
authors.initials: MY
authors.lastname: Donath
authors.forename: Iris K
authors.initials: IK
authors.lastname: Penner
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D004311:Double-Blind Method; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C547697:gevokizumab